more_reports

Mass. Biotech Shares Strong Q3 Results

Research Report
  ()
Kiniksa Pharmaceuticals Ltd. (KNSA:NASDAQ) recently reported strong Q3 2024 earnings, which led to its Outperform rating, according to a Wedbush research note.
Tags: Biotechnology / Pharmaceuticals

Boston Biotech Announces Novartis Collaboration

Research Report
  ()
Monte Rose Therapeutics Inc. (GLUE:NASDAQ) recently unveiled a collaborative agreement with Novartis for the development of MRT-6160, its VAV1-degrader program, according to a Wedbush research note.
Tags: Biotechnology / Pharmaceuticals

Regenerative Medicine Co. May Have Solution to Delivering Cell Treatments

  ()
This Canadian life sciences firm is developing an implantable cell-containing pouch, shown in clinical trial data thus far to be safe, well-tolerated and effective. Learn why several analysts rate the company Buy.
Tags: Regenerative MedicineMedical Devices

H.C. Wainwright & Co. Raises Price Target on Biotech Following Positive Regulatory Updates

Research Report
  ()
DBV Technologies SA (DBVT:NASDAQ) received a raised target price after it released long-awaited regulatory clarity regarding the path forward for its Viaskin Peanut patch.
Tags: Biotechnology / Pharmaceuticals

Silver Break Out Confirmed

Contributed Opinion
  ()
The silver break out is confirmed, and Ron Struthers of Struthers Resource Stock Report expects a move to $50. He explains why he believes Coeur Mining Inc. (CDE:NYSE) offers good value and shares one biotech stock he believes is currently a sell.
Tags: SilverBiotechnology / PharmaceuticalsGold

NY Biopharma Shares Promising Clinical Data

Research Report
  ()
Anavex Life Sciences Corp. (AVXL:NASDAQ) recently released encouraging preliminary electroencephalography (EEG) biomarker results from Part A of the ongoing Phase 2 clinical study of ANAVEX3-71 for schizophrenia treatment, according to an H.C. Wainright & Co. research note.
Tags: Biotechnology / Pharmaceuticals

H.C. Wainwright & Co. Shares Buy Rating on Biotech Co.

Research Report
  ()
H.C. Wainwright & Co. analysts gave Unicycive Therapeutics Inc. (UNCY:NASDAQ) a Buy rating after the company announced the successful completion of the Phase 1 study for UNI-494 in healthy volunteers.
Tags: Biotechnology / Pharmaceuticals

Is This AI Healthcare Stock Worth Being Overweight On?

Contributed Opinion
  ()
Technical Analyst Clive Maund explains why he thinks Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) is a Strong Buy and worth being overweight on.
Tags: Healthcare ServicesTechnologyLife Sciences Tools & Diagnostics

Mass. Biotech Receives FDA Approval

Research Report
  ()
Biofrontera Inc. (BFRI:NASDAQ) receieved FDA's approval of the company's supplemental Biologics License Application (sBLA) to expand the use of Ameluz for treating larger surface areas of actinic keratosis (AK) on the face and scalp, according to a Roth MKM research note.
Tags: Biotechnology / Pharmaceuticals

CT Biotech Ready for Clinical Milestones

Research Report
  ()
Trevi Therapeutics Inc. (TRVI:NASDAQ) has made progress in its clinical trials for Haduvio, particularly in treating chronic cough in idiopathic pulmonary fibrosis (IPF) patients and refractory chronic cough (RCC), according to an EF Hutton research note.
Tags: Biotechnology / Pharmaceuticals

Biotech Completes Last Patient Visit in Phase2b Osteosarcoma Trial

Research Report
  ()
Following OS Therapies Inc.'s (OSTX:NYSEAMERICAN) announcement that the last patient enrolled in their Phase 2b trial for OST-HER2 in recurred, resected Osteosarcoma (OS) has completed their final radiographical evaluation, the company received a Buy rating and high target price from EF Hutton.
Tags: Biotechnology / Pharmaceuticals

New Jersey Biotech Reports Positive Survival Data

Research Report
  ()
H.C. Wainwright & Co. analysts Dr. Joseph Pantginis gave PDS Biotechnology Corp. (PDSB:NASDAQ) a Buy rating and large target price.
Tags: Biotechnology / Pharmaceuticals

California Biotech's Target Price 200% Higher Than Current

Research Report
  ()
F Hutton analyst Jason Kolbert gave Anixa Biosciences Inc. (ANIX: NASDAQ) a high target price after it had announced it would be amending the protocol for its ongoing CAR-T therapy clinical trial for ovarian cancer, allowing for a second dose in certain patients.
Tags: Biotechnology / Pharmaceuticals

Target Price Raised on Biotech Co.

Research Report
  ()
In an updated assessment of Zymeworks Inc.'s (ZYME:NYSE; ZYME:TSX) pipeline potential and upcoming catalysts, H.C. Wainwright & Co. analysts raised their target price on the company.
Tags: Biotechnology / Pharmaceuticals

CA Pharma Co. Reports Positive Phase 3 Data for Schizophrenia Treatment

Research Report
  ()
Reviva Pharmaceuticals Holdings Inc. (RVPH: NASDAQ) recently reported positive Phase 3 data for its Schizophrenia treatment. The company also noted it intends to file an NDA in the first quarter of 2026, according to an EF Hutton Research note.
Tags: Biotechnology / Pharmaceuticals

AI Collaboration to Streamline Healthcare Administration and Improve Patient Outcomes

  ()
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has formally entered a collaborative agreement with UK-based AI healthcare technology company SPRYT Limited. Read how this partnership aims to change the way patients interact with their healthcare providers.
Tags: Healthcare Services

Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Revolutionizing Chronic Disease Treatment Through Regenerative Medicine

  ()
A regenerative medicine therapeutics company focused on developing technologies to address chronic diseases through a regenerative approach, Sernova Corp. (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) is focused on reforming healthcare through technology. See why experts and analysts are praising this company's potential.
Tags: Medical DevicesBiotechnology / Pharmaceuticals

Implanted Cell Device Reaches 5 Year Milestone

Research Report
  ()
This pouch, loaded with pancreatic islet cells, is being evaluated in patients with insulin-dependent Type 1 diabetes, noted a Ventum Capital Markets report.
Tags: Medical DevicesRegenerative Medicine

Is It Now Time To Buy This Biotech Stock?

Contributed Opinion
  ()
Technical Analyst Clive Maund shares his thoughts on Sernova Corp. (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) to explain why he believes it is a good stock to accumulate, between the current price and recent lows.
Tags: Biotechnology / PharmaceuticalsMedical Devices

Co's. Cell Pouch Performs Well in Study

Research Report
  ()
Data show the device keeps the incorporated therapeutic cells alive and functioning for at least five years, noted a Leede Financial Inc. report.
Tags: Regenerative MedicineMedical Devices

Trial Data Help Position Cell Pouch for Commercial Success

Research Report
  ()
The upside implied in the target price on this Canadian firm, developing regenerative medicine platform technologies, is 1,900%, noted an H.C. Wainwright & Co. report.
Tags: Medical DevicesRegenerative Medicine